Abstract
Background A well-known blood biomarker (soluble fms-like tyrosinase-1 [sFLT-1]) for preeclampsia, i.e., a pregnancy disorder, was found to predict severe COVID-19, including in males. True biomarker may be masked by more-abrupt changes related to endothelial instead of placental dysfunction. This study aimed to identify blood biomarkers that represent maternal-fetal interface tissues for predicting preeclampsia but not COVID-19 infection.
Methods The surrogate transcriptome of the tissues was determined by that in maternal blood, utilizing four datasets (n=1,354) which were collected before the COVID-19 pandemic. Applying machine learning, a preeclampsia prediction model was chosen between those using blood transcriptome (differentially expressed genes [DEGs]) and the blood-derived surrogate for the tissues. We selected the most predictive model by the area under receiver operating characteristic (AUROC) using a dataset for developing the model, and well-replicated in datasets either with or without intervention. To identify eligible blood biomarkers that predicted any-onset preeclampsia from the datasets but did not predict positives in the COVID-19 dataset (n=47), we compared several methods of predictor discovery: (1) the best prediction model; (2) gene sets by standard pipelines; and (3) a validated gene set for predicting any-onset preeclampsia during the pandemic (n=404). We chose the most predictive biomarkers from the best method with the significantly largest number of discoveries by a permutation test. The biological relevance was justified by exploring and reanalyzing low- and high-level, multi-omics information.
Results A prediction model using the surrogates developed for predicting any-onset preeclampsia (AUROC of 0.85, 95% confidence interval [CI] 0.77 to 0.93) was the only that was well-replicated in an independent dataset with no intervention. No model was well-replicated in datasets with a vitamin D intervention. None of the blood biomarkers with high weights in the best model overlapped with blood DEGs. Blood biomarkers were transcripts of integrin-α5 (ITGA5), interferon regulatory factor-6 (IRF6), and P2X purinoreceptor-7 (P2RX7) from the prediction model, which was the only method that significantly discovered the eligible blood biomarkers (n=3/100 combinations, 3.0%; P=.036). Most of the predicted events (73.70%) among any-onset preeclampsia were cluster A as defined by ITGA5 (Z-score ≥1.1), but were only a minority (6.34%) among positives in the COVID-19 dataset. The remaining were the predicted events (26.30%) among any-onset preeclampsia or those among COVID-19 infection (93.66%) if IRF6 Z-score was ≥-0.73 (clusters B and C), in which none was the predicted events among either late-onset preeclampsia (LOPE) or COVID-19 infection if P2RX7 Z-score was <0.13 (cluster B). Greater proportion of predicted events among LOPE were cluster A (82.85% vs. 70.53%) compared to early-onset preeclampsia (EOPE). The biological relevance by multi-omics information explained the biomarker mechanism, polymicrobial infection in any-onset preeclampsia by ITGA5, viral co-infection in EOPE by ITGA5-IRF6, a shared prediction with COVID-19 infection by ITGA5-IRF6-P2RX7, and non-replicability in datasets with a vitamin D intervention by ITGA5.
Conclusions In a model that predicts preeclampsia but not COVID-19 infection, the important predictors were maternal-blood genes that were not extremely expressed, including the proposed blood biomarkers. The predictive performance and biological relevance should be validated in future experiments.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by: (1) the Lembaga Penelitian dan Pengabdian kepada Masyarakat (LPPM) Universitas Nahdlatul Ulama Surabaya in Indonesia (grant no.: 161.5.1/UNUSA/Adm-LPPM/III/2021) to Herdiantri Sufriyana; (2) the Ministry of Science and Technology (MOST) in Taiwan (grant nos.: MOST109-2221-E-038-018 and MOST110-2628-E-038-001) to Emily Chia-Yu Su; and (3) the Higher Education Sprout Project from the Ministry of Education (MOE) in Taiwan (grant no.: DP2-110-21121-01-A-13) to Emily Chia-Yu Su. These funding bodies had no role in the study design; in the collection, analysis, and interpretation of the data; in the writing of the report; or in the decision to submit the article for publication.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Source data were openly available before the initiation of the study. Here are the links to the download pages of the original data sources: https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE73685 https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE108497 https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE85307 https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE86200 https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE149437 https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE177477 https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE192902
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced are available online at: https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE73685 https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE108497 https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE85307 https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE86200 https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE149437 https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE177477 https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE192902